Enlivex Receives IMOH Regulatory Authorization for a Phase I/II Trial Evaluating Allocetra in Knee Osteoarthritis Patients
Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has received authorization from the Israeli Ministry of Health (IMOH) to initiate a multi-country, double-blind, randomized, placebo-controlled Phase I/II trial. This trial aims to evaluate the efficacy, safety, and tolerability of Allocetra, Enlivex’s novel immunotherapy, in patients with moderate to severe knee osteoarthritis.
Osteoarthritis (OA) is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, swelling, and stiffness. It is estimated that more than 300 million people worldwide suffer from OA, making it one of the most prevalent musculoskeletal disorders. Current treatment options for OA focus on managing symptoms, and there is a significant unmet need for disease-modifying therapies that can slow down or halt the progression of the disease.
Allocetra, developed by Enlivex, is a revolutionary immunotherapy that aims to reprogram macrophages, a type of immune cell, in order to restore immune homeostasis and prevent tissue damage. By modulating the inflammatory response, Allocetra has the potential to alleviate the symptoms and slow down the progression of OA.
The Phase I/II trial will involve up to 160 patients with moderate to severe symptomatic knee osteoarthritis. These patients will receive injections of Allocetra directly into the affected knee joint. The trial will be double-blind, meaning that neither the patients nor the researchers will know which patients are receiving the investigational treatment or the placebo.
The primary s of the trial are to evaluate the efficacy of Allocetra in reducing pain, improving joint function, and reducing disease progression in knee osteoarthritis patients. Secondary s include assessing safety and tolerability, as well as evaluating various biomarkers to gain insights into Allocetra’s mechanism of action.
If successful, this trial could potentially offer a breakthrough treatment option for knee osteoarthritis patients. Given the significant patient population suffering from OA and the lack of disease-modifying therapies, Allocetra holds promise as a novel therapeutic approach.
Dr. Itai Peretz, CEO of Enlivex, expressed his enthusiasm for the initiation of this trial and the potential impact of Allocetra on knee osteoarthritis patients. He stated, We are thrilled to commence this Phase I/II trial evaluating Allocetra in knee osteoarthritis patients. If successful, Allocetra may represent a paradigm shift in the treatment of this debilitating disease. We look forward to advancing the trial and generating data to support its potential approval in the future.
Enlivex aims to conduct the Phase I/II trial in multiple countries to ensure a diverse patient population and increase the generalizability of the results. This approach allows for a comprehensive evaluation of Allocetra’s efficacy and safety profile across different populations, which is crucial for regulatory approval and subsequent commercialization.
In conclusion, Enlivex’s receipt of regulatory authorization for the initiation of a Phase I/II trial evaluating Allocetra in knee osteoarthritis patients marks a significant milestone in the development of this innovative immunotherapy. With the potential to address the unmet need for disease-modifying therapies in osteoarthritis, Allocetra brings hope to millions of patients worldwide. As the trial progresses, the scientific community eagerly anticipates the results and the possibility of a groundbreaking treatment for knee osteoarthritis.
Comments